Therapeutic profile of patients with diabetes treated at the first level of health care by Maidana, Gladys Mabel et al.
Asclepius Medical Research and Reviews • Vol 3 • Issue 2 •  2020 1
INTRODUCTION
Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications derived from progressive damage to the kidney, 
retina, blood vessels, heart, and nervous system.[1] DM2 has 
a significant growth in its prevalence in recent years due 
to the process of industrialization and urbanization of the 
population, reaching today values of a global epidemic health 
problem.[2,3] According to the World Health Organization 
(WHO), there are more than 347 million people with diabetes 
in the world.[4]
DM2 is currently one of the leading causes of death,[4]
increasing that risk of decease at least twice when compared 
with the population without diabetes.[4]
The research carried out by the National Diabetes Program 
of the Ministry of Public Health and Social Welfare in 
Paraguay,[5] established that 9.7% of the population 700,000 
people suffer from diabetes while 1,125,000 are in the pre-
diabetic stage. In Argentina, prevalence is more than 10% for 
the adult population (4 million inhabitants).[6]
Diabetes is a silent disease that can emerge at any age for two 
reasons: (1) Due to a lack of insulin secretion, which causes 
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Introduction: Diabetes mellitus type 2 (DM2) is a chronic metabolic disease frequently associated with late complications 
derived from progressive damage several tissues. When patients with DM2 do not respond adequately to non-pharmacological 
measures, anti-diabetic agents should be indicated to avoid the long-term risk of macro and microvascular complications. 
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patients were treated with biguanides (metformin) and 23.5% with oral hypoglycemic agents; 21.7% with a combination of 
both anti-diabetic groups; and 3.5% with other therapeutically options (glitazones, meglitinides, SGLT2 inhibitors, and GLP-1 
agonist). All the cases of new drug indications were register in Argentina while in Paraguay; all drugs prescribed were considered 
essential medicines. Conclusion: Diabetes is a frequent disease that causes severe disabilities and death in the affected population. 
Although it exists several drugs for DM2 treatment, only a few of them follow the rational use of medicines guidelines, while 
other drugs might be unsafe and certainly more expensive than essential options. Since first level health-care therapeutic strategy 
plays a major role in avoiding complications from diabetes, countries with low or middle income such as Paraguay or Argentina 
should do efforts to provide to all patients a rational treatment. This work shows that not in all scenarios, this pattern is true.
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Type 1 diabetes or (2) due to inadequate secretion of it, which 
leads to the appearance of Type 2 diabetes (DM2). This 
disease is not curable, but it can be controlled with adequate 
treatment. To accomplish this objective, it is necessary to 
maintain optimal blood glucose levels.[7]
Diabetes treatment is based on three principles: Education, 
lifestyle changes, and, if necessary, and pharmacological options. 
When the patient with DM2 does not respond adequately to diet 
or fails to comply with non-drug measures, antidiabetic agents 
should be indicated to promote glycemic control and lead to 
decreased levels of glycated hemoglobin (HbA1c).[8] The level 
of DM2 control, assessed by HbA1c, influences the long-term 
risk of macro and microvascular complications.[9]
Given the frequent association of diabetes with hypertension/
dyslipidemia/excess weight, the control of these risk factors 
is an integral and main part of the control of diabetes itself.[9]
The pharmacist, through its pharmaceutical interventions, has 
demonstrated over the past years, a role in improving health 
outcomes for patients, especially those with chronic diseases.[10]
According to the WHO, pharmaceutical care is “a concept of 
health professional practice in which the patient is the main 
beneficiary of the pharmacist’s actions. Pharmaceutical care 
is the compendium of attitudes, behaviors, commitments, 
concerns, values ethics, roles, knowledge, responsibilities, 
and skills of pharmacists in the provision of pharmacotherapy 
with the aim of obtaining defined therapeutic results in the 
health and quality of life of the patient.”[11]
Therapeutic efficacy can be increased through pharmaceutical 
care actions that may warrant the proper dosage, absorption, 
drug compliance, and treatment adherence.[12]
The objective of this study was to evaluate the therapeutic 
profile of diabetic patients cared by the first level of the health 




This study was an observational descriptive cross-section 
study.
Study universe
Diabetic patients from the Cordillera District, Republic 
of Paraguay and La Plata Capital City of Buenos Aires, 
Argentina.
Analysis unit
Diabetic patients treated at the Family Health Unit (USF) 
of Cabañas, City of Caacupé, Cordillera, Paraguay, and the 





January 1, 2017, to December 31, 2019.
Information source
Review of medical records.
Study variables
This study was Age, sex, date of onset of the disease, clinical 
signs of diabetes complications, diastolic and systolic blood 
pressure, abdominal circumference, and pharmacological 
treatment for anti-diabetic and anti-hypertensive drugs.
Data collection instrument
Spreadsheet specially designed for the study, in where 
sociodemographic data, years of evolution of the disease, 
antidiabetic drugs used, and the comorbidities were recorded.
Data analysis
The data obtained were grouped, processed, and analyzed 
through descriptive statistics using Microsoft Office Excel® 
software.
Ethical aspects
The proposal and protocol of this work were evaluated 
and approved by the Ethics Committee of the Faculty of 
Chemical Sciences of the National University of Asunción 
(code CEI-383/17).
RESULTS
Five hundred seventy-six patients were enrolled in the study. 
Their age was 59.6 ± 10.2 years old, and the distribution 
of patients by sex was women (398/576) 69.09% and men 
(178/576) 38%. The time of disease evolution of patients at 
the moment where they were enrolled was 4.8 ± 3.5 years.
The main risk factors found were hypertension in 63.7% 
of cases, obesity in 21.9%, and an increase in abdominal 
circumference 69.1% of men and 63.4% of women [Table 1].
Laboratory data indicated a high presence of dyslipidemia 
63.5% (57.4% in Argentina and 66.4% in Paraguay), total 
cholesterol >200 mg/dL in 31.6% (32.3% and 30.7%, 
respectively), triglycerides >150 mg/dL in 48.8% (47.9% and 
49.7%), and HDL sub-optimal cholesterol in 40.5% of the 
cases (40.1% and 40.8%, respectively in each country).
Regarding treatment received, 30.6% of the patients were treated 
with biguanides (metformin), 23.5% with oral hypoglycemic 
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agents; 21.7% with a combination of both anti-diabetic groups; and 
3.5% of other therapeutically options (glitazones, meglitinides, 
SGLT2 inhibitors, and GLP-1 agonist) [Tables 2-5].
DISCUSSION
Once changes in lifestyle, diet, and exercise have not 
been able to obtain the therapeutic goals, pharmacological 
treatment is a valid option to achieve metabolic control not 
only guaranteeing HbA1c levels <6.5% but also avoiding 
cardiovascular complications such as myocardial infarction, 
stroke, blindness, or kidney failure.
The treatment of Type 2 diabetes is divided into three 
therapeutic steps. In the first step, metformin should be 
considered since it was shown to reduce complications 
and mortality associated with this disease.[13] Only in some 
cases, oral hypoglycemic agents such as sulfonylureas can be 
indicated as initial monotherapy, but the association with other 
drugs is still controversial in this step.[14] The second step is 
the addition of a second synergistic drug in combination with 
metformin. Finally, the third step involves the introduction of 
insulin as a preferred option over oral options.
Other therapeutical alternatives are glitazones, meglitinides, 
SGLT2 inhibitors, and GLP-1 agonist that may collaborate 
in controlling surrogate variables such as blood glucose or 
HbA1c levels, were not able yet to demonstrate a significant 
reduction of complications or mortality from diabetes, hence 
are not a valid option for the first level of health care in term 
of their benefit/risk ratio.
The study shows that in the first level of health care in La 
Plata (Argentina), 7% of the patients with diabetes were 
prescribed with non-classical treatment such as glitazones, 
meglitinides GLP-1 agonist, or SGLT2 inhibitors, while in 
Paraguay nobody received that type of drugs.
On the other hand, regarding insulin therapy, no clear benefits 
on the efficacy of short-acting or long-acting insulin analogs 
over regular human insulin in people with Type 2 diabetes 
have been demonstrated[15] and those new options insulin 
alternatives are much more expensive. For this reason, in the 
first level health system, regular insulin should be the choice, 
concept that is respected in Paraguay but not in Argentina.
About Glitazones, DPP-4 inhibitors, or GLP-1 analogs, these 
options did not demonstrate the influence the risk of DM2 
evolution or tissue injury reduction due to DM2 complications 
when compared with placebo.[16,17]
The rational use of medicine (RUM) rules indicates that 
medicines should demonstrate efficacy to change the natural 
Table 1: Risk measurement parameters in patients enrolled in the study
Risk (n=576) (average±SD) Caacupé La Plata
Systolic blood pressure (mmHg) 143.44±9.1 136.67±9.93 149.52±9.7
Diastolic blood pressure (mmHg) 87.89±7.2 87.24±6.24 88.49±5.4
Optimal blood pressure 1.8 1.3 2.1
Normal blood pressure 13.9 13.2 14.7
High normal blood pressure 20.6 23.7 18.5
Grade I hypertension 63.7 61.8 64.7
BMI (kg/m2) 28.6±7.3 27.6±4.3 28,6±6.4
(18.5–24.9) optimal 26.7 24.3 29.2
(25–29.9) overweight 50.3 50.0 50.6
(>30) obesity 21.9 23.7 20.2
Abdominal circumference
Without risk (cm)
Male (<94) M:62.8 M:65.5 M:60.1
Female (<80) F:26.3 F:23.4 F:29.2
Moderate risk (cm)
Male (>94 <102) M:28.2 M:24.2 M:32.2
Female (>80 <88) F:20.2 F:19.2 F:21.3
High risk (cm)
Male (≥102) M:9.5 M:10.4 M:8.7
Female (≥88) F:53.35 F:57.4 F:49.5
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history of a disease, safety, and access to the lowest price 
for the patient and the health system. That features are all 
guarantee by metformin, sulfonylurea, or insulin (regular and 
NPH), so these medicines must be part of the list of essential 
medicines for diabetes treatment at the first level of health-
care system.
CONCLUSION
This work demonstrates a still great variability in the RUM 
profile, associate with diabetes treatment in the first level of 
health-care system of middle-low income countries such as 
Argentina or Paraguay. Efforts should be done to guarantee 
access to a therapeutic option that demonstrated the best cost/
effectiveness ratio, to provide drugs with proven efficacy, 
safety, and reasonable cost to this population.
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Hypertension+DM2 68 24.1 28.5
Therapy n=576 (%) Caacupé La Plata
Monotherapy 26.7 27.1 26.2
Complex (2–4 drugs) 66.2 68.3 64.1
Polymedication (5 or 
more drugs)
7.1 4.6 9.7
Table 5: Insulin type
Insulin type n: 76 (%) Caacupé La Plata
NPH 7.2 6.6 7.8
Lispro 4.7 3.9 5.6
Crystalline 5.0 7.9 4.4
Without Insulin 82.1 81.6 82.6
AQ3
Table 3: Antihypertensive drugs
Antihypertensive 
drug type
n: 568 (%) Caacupé La Plata
Betablockers 2.8 4.3 2.4
IECA 64.7 64.7 58.7
CA 5,9 5.9 5.9
Diuretics 0 2.3 1.3
Ara II 3.5 4.3 17.9
Combinations 20.7 18.5 23.8
AQ3
AQ3 Table 4: Anti-diabetic drugs
Type of oral 
anti-diabetics
n: 576 (%) Caacupé La Plata
Metformin 30.6 11.8 49.4
Glimepiride 17.4 23.7 11.2
Glipizide 5.2 0 10.4
Chlorpropamide 0.9 0 1.9





Diet (exclusively) 29.4 38.8 20.1
AQ3
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